Nanozyme-Enhanced Probiotic Spores Regulate the Intestinal Microenvironment for Targeted Acute Gastroenteritis Therapy.

Abstract

Antibiotic therapeutics to combat intestinal pathogen infections often exacerbate microbiota dysbiosis and impair mucosal barrier functions. Probiotics are promising strategies, because they inhibit pathogen colonization and improve intestinal microbiota imbalance. Nevertheless, their limited targeting ability and susceptibility to oxidative stress have hindered their therapeutic potential. To tackle these challenges, Ces₃ is synthesized by <i>in situ</i> growth of CeO₂ nanozymes with positive charges on probiotic spores, facilitating electrostatic interactions with negatively charged pathogens and possessing a high reactive oxygen species (ROS) scavenging activity. Importantly, Ces₃ can resist the harsh environment of the gastrointestinal tract. In mice with <i>S.</i> Typhimurium-infected acute gastroenteritis, Ces₃ shows potent anti-<i>S.</i> Typhimurium activity, thereby alleviating the dissemination of <i>S.</i> Typhimurium into other organs. Additionally, owing to its O₂ deprivation capacity, Ces₃ promotes the proliferation of anaerobic probiotics, reshaping a healthy intestinal microbiota. This work demonstrates the promise of combining antibacterial, anti-inflammatory, and O₂ content regulation properties for acute gastroenteritis therapy.